References of "Belgian Journal of Hematology"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailWaldenström's macroglobulinaemia: Belgian Hematology Society guidelines
VAN HENDE, V.; BRON, D.; VAN DEN NESTE, E. et al

in Belgian Journal of Hematology (2015), 6(4), 142-151

Waldenström’s macroglobulinaemia is a B-cell disorder characterised by bone marrow infiltration with lymphoplasmacytic cells, along with demonstration of an IgM monoclonal gammopathy in the blood. This ... [more ▼]

Waldenström’s macroglobulinaemia is a B-cell disorder characterised by bone marrow infiltration with lymphoplasmacytic cells, along with demonstration of an IgM monoclonal gammopathy in the blood. This condition belongs to the lymphoplasmacytic lymphomas as defined by the World Health Organization classification (ICD-0 code 9671/3). Approximately one-fourth of patients are asymptomatic. Clinical features of the symptomatic patients are diverse and may relate to overall disease burden (such as peripheral blood cytopaenias, organomegaly and constitutional symptoms) or may be directly attributable to the IgM paraprotein. The latter include hyperviscosity syndrome, amyloidosis, peripheral neuropathy and cold haemagglutinin. Therapeutic options have traditionally involved alkylating agents, nucleoside analogues, and rituximab, either as single therapy or in combination. However, emerging new data on combination therapy as well as novel agents have shown encouraging results. This report provides the Belgian Hematology Society guidelines according to recent clinical studies. [less ▲]

Detailed reference viewed: 29 (0 ULg)
Full Text
Peer Reviewed
See detailHighlights of the 13th International Conference on Malignant Lymphoma
BONNET, Christophe ULg; BOSLY, A.

in Belgian Journal of Hematology (2015), 6(4), 173-178

A lot of interesting data were presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland. The authors summarise below those presentations/abstracts they found relevant ... [more ▼]

A lot of interesting data were presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland. The authors summarise below those presentations/abstracts they found relevant for daily practice, either now or in the near future. [less ▲]

Detailed reference viewed: 46 (0 ULg)
Full Text
Peer Reviewed
See detailBHS guidelines for the treatment of Burkitt lymphoma
BONNET, Christophe ULg; Janssens, A.; Wu, KL. et al

in Belgian Journal of Hematology (2015), 6(2), 61-69

Burkitt lymphoma (BL) is a rare but very aggressive non-Hodgkin’s lymphoma characterized by an isolated translocation t(8;14)(q24;q32). The sporadic form is the subentity most frequently encountered in ... [more ▼]

Burkitt lymphoma (BL) is a rare but very aggressive non-Hodgkin’s lymphoma characterized by an isolated translocation t(8;14)(q24;q32). The sporadic form is the subentity most frequently encountered in our country. Diagnosis and initial work-up must be completed rapidly to start treatment as soon as possible. Positron emission tomography (PET) scan is useful for initial staging and to evaluate the chemosensitivity of the tumor during and after treatment. After debulking, it is recommended to add rituximab to chemotherapy. Currently intensive short-cycle chemotherapies (ISCC) and low intensity chemotherapies (LIC) are two valuable options. Radiotherapy is not indicated except in case of central nervous system involvement. Patients achieving complete remission must be followed carefully during the first year to detect recurrence of the disease. More than 80% of patients sustain their remission one year following initial treatment and are considered cured. For patients in partial remission or with chemosensitive relapse, autologous stem cell transplantation is recommended following re-induction with non-cross-resistant polychemotherapy. Monitoring complete blood counts and cognitive functions is important to detect late toxicity of the applied therapies. [less ▲]

Detailed reference viewed: 190 (15 ULg)
Full Text
See detailThe anti-angiogenic peptide Anginex blocks osteoclastogenesis
Muller, Joséphine ULg; Binsfeld, Marilène ULg; DUBOIS, Sophie ULg et al

in Belgian Journal of Hematology (2015), Abstracts book

Detailed reference viewed: 21 (8 ULg)
Full Text
Peer Reviewed
See detailEpidemiological data on sickle cell disease in Belgium
Ketelslegers, Olivier; Eyskens, François; BOEMER, François ULg et al

in Belgian Journal of Hematology (2015), 6(4), 135-141

Detailed reference viewed: 22 (1 ULg)
Full Text
Peer Reviewed
See detailPractical management of Chronic Myeloid Leukemia in Belgium
Benghiat, FS.; Beguin, Yves ULg; Dessars, B. et al

in Belgian Journal of Hematology (2015), 6(1), 16-32

Imatinib has drastically changed the outcome of patients with chronic myeloid leukemia (CML), with the majority of them showing a normal life span. Recently, the development of second and third generation ... [more ▼]

Imatinib has drastically changed the outcome of patients with chronic myeloid leukemia (CML), with the majority of them showing a normal life span. Recently, the development of second and third generation tyrosine kinase inhibitors (TKIs) and the possibility of treatment discontinuation made the management of these patients more challenging. In this review, practical management guidelines of CML are presented, adapted to the Belgian situation in 2014. In first line chronic phase patients, imatinib, nilotinib and dasatinib can be prescribed. While second generation TKIs give faster and deeper responses, their impact on long-term survival remain to be determined. The choice of the TKI depends on CML risk score, priority for a deep response to allow a treatment-free remission protocol, age, presence of comorbid conditions, side effect profile, drug interactions, compliance concerns and price. Monitoring the response has to be made according the 2013 ELN criteria, and is based on the bone-marrow cytogenetic response during the first months and on the blood molecular response. Molecular follow-up is sufficient in patients with a complete cytogenetic response. For patients who fail frontline therapy, nilotinib, dasatinib, bosutinib and ponatinib are an option depending of the type of intolerance or resistance. T315I patients are only sensitive to ponatinib, which has to be carefully handled due to cardiovascular toxicity. Advanced phase diseases are more difficult to handle, with treatments including allogeneic stem cell transplantation, which is also an option for patients failing at least two TKIs. The possibility of treatment-free remission and pregnancy are also discussed. [less ▲]

Detailed reference viewed: 187 (5 ULg)
Full Text
Peer Reviewed
See detailImpact of graft source and composition on outcomes after allogeneic stem cell transplantation
SERVAIS, Sophie ULg; Baron, Frédéric ULg; BEGUIN, Yves ULg

in Belgian Journal of Hematology (2015), 6(4), 162-168

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailHaemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency
SID, Sélim ULg; Dugauquier, Christophe; DE PRIJCK, Bernard ULg et al

in Belgian Journal of Hematology (2015), 6(2), 74-78

We present a patient with Burkitt's lymphoma who suffered a severe haemolytic crisis after treatment with rasburicase. This case report underlines the high incidence of glucose-6-phosphate dehydrogenase ... [more ▼]

We present a patient with Burkitt's lymphoma who suffered a severe haemolytic crisis after treatment with rasburicase. This case report underlines the high incidence of glucose-6-phosphate dehydrogenase deficiency in some ethnic groups and the importance of a detailed patient and family history before starting treatment, even in case of emergency. Glucose-6-phosphate dehydrogenase is an essential enzyme since it makes the synthesis of NADPH + H from NADP possible, which determines the reducing power (NADPH) of the cell. Every defect in this physiological process, notably glucose-6-phosphate dehydrogenase deficiency, may thus result simultaneously with the use of rasburicase in acute or chronic haemolysis according to the importance of the deficiency. Management is based on stopping the incriminated drug and on supportive therapy consisting of administering packed red blood cells if the anaemia is poorly tolerated. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailTreatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society
MOURIN, E.; VAN HOOF, A.; BOSLY, A. et al

in Belgian Journal of Hematology (2014), 5

Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% of ... [more ▼]

Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% of all non-Hodgkin's lymphomas. Mantle cell lymphoma generally affects patients over 60 years-old. Most patients have advanced disease (>70 % Ann Arbor stage IV). Several efforts have been made to predict outcome in mantle cell lymphoma. The cell-proliferation marker Ki-67, the Mantle Cell Lymphoma International Prognostic Index, fluorodeoxyglucose positron emission tomography and minimal residual disease are prognostic tools. For young patients, chemoimmunotherapy followed by high-dose chemotherapy plus stem cell transplantation is the treatment of choice. For the main group of older patients, chemo-immunotherapy followed by maintenance with rituximab is the gold standard. In relapses, temsirolimus is actually registered and new drugs, such as ibrutinib, are currently evaluated with promising preliminary results.2 [less ▲]

Detailed reference viewed: 64 (0 ULg)
Full Text
See detailA summary of the BVAC/ABCA program hosted by the general annual meeting of the BHS in Ghent on Friday, January 31st, 2014.
GOTHOT, André ULg; KORNREICH, A.

in Belgian Journal of Hematology (2014), 5(2), 72-6

Detailed reference viewed: 16 (5 ULg)
Full Text
Peer Reviewed
See detailBHS guidelines for the treatment of marginal zone lymphomas.
BRON, D.; VAN DEN NESTE, E.; KENTOS, A. et al

in Belgian Journal of Hematology (2014), 5

Marginal zone lymphomas are a heterogeneous subtype of indolent B-non-Hodgkin Lymphoma that includes three distinct diseases: Extranodal mucosa associated lymphoid tissue lymphoma, nodal marginal zone ... [more ▼]

Marginal zone lymphomas are a heterogeneous subtype of indolent B-non-Hodgkin Lymphoma that includes three distinct diseases: Extranodal mucosa associated lymphoid tissue lymphoma, nodal marginal zone lymphoma and splenic marginal zone lymphoma lymphocytes +/- villous lymphocytes. The different diagnosis, work up and treatment options are discussed in these guidelines. [less ▲]

Detailed reference viewed: 51 (0 ULg)
Full Text
Peer Reviewed
See detailGalectin expression in the multiple myeloma microenvironment
Muller, Joséphine ULg; CAERS, Jo ULg; Binsfeld, Marilène ULg et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 33 (12 ULg)
Full Text
Peer Reviewed
See detailHemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency.
SID, Sélim ULg; Dugauquier, D.; DE PRIJCK, Bernard ULg et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 53 (9 ULg)
Full Text
Peer Reviewed
See detailVaccination guidelines in hematopoietic transplant patients : recommendations from the BHS Transplant Committee
Moors, I.; Schoemans, H.; Callens, S. et al

in Belgian Journal of Hematology (2014), 6

Over the past years, hematopoietic stem cell transplantation (HSCT) is increasingly used as a consolidation therapy in several haematological diseases and solid tumours. In the post-transplantation period ... [more ▼]

Over the past years, hematopoietic stem cell transplantation (HSCT) is increasingly used as a consolidation therapy in several haematological diseases and solid tumours. In the post-transplantation period, the immunity of HSCT recipients is impaired due to toxicity of the pre-HSCT treatment (chemo- and/or radiotherapy) and the conditioning regimen with reset of the immune system and – in case of allogeneic stem cell transplantation – possible graft-versus-host-disease (GVHD) and use of immunosuppressive drugs. This leads to a considerably increased risk of infections, with higher morbidity and mortality in these patients. Therefore, prevention of infections, through antibiotic prophylaxis, life style adjustments, germfree nutrition and revaccination, is of major importance to improve outcomes. In this article we present the Belgian guidelines for vaccination after hematopoietic stem cell transplantation, based on available data in the literature and international guidelines, taking into account the availability of vaccines and - if applicable - their reimbursement in Belgium. We present a general vaccination schedule for post-HSCT patients, a proposition for pre-transplant vaccination and donor vaccination, and an overview of special indications such as travel vaccinations and vaccinations of close contacts and health care workers, with guidelines for titer follow up. [less ▲]

Detailed reference viewed: 67 (4 ULg)
Full Text
See detailMultiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines
Binsfeld, Marilène ULg; Heusschen, Roy ULg; Lamour, Virginie et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 29 (11 ULg)